首页 | 本学科首页   官方微博 | 高级检索  
检索        

国家基本药物制度的现状及其完善对策探讨
引用本文:覃正碧,汪志宏,程刚,李元启,左小平,卢祖洵,向继洲.国家基本药物制度的现状及其完善对策探讨[J].中国药房,2008,19(14):1041-1044.
作者姓名:覃正碧  汪志宏  程刚  李元启  左小平  卢祖洵  向继洲
作者单位:1. 华中科技大学同济医学院公共卫生学院,武汉市,430003;华中科技大学同济医学院附属梨园医院,武汉市,430071
2. 华中科技大学同济医学院附属梨园医院,武汉市,430071
3. 国家食品药品监督管理局药品评价中心,北京市,100045
4. 湖北省食品药品监督管理局/药品不良反应监测中心,武汉市,430071
5. 湖北省恩施州食品药品监督管理局,恩施市,445000
6. 华中科技大学同济医学院公共卫生学院,武汉市,430003
摘    要:目的:完善国家基本药物制度,满足公众的健康医疗需求。方法:采用文献研究、对比分析方法,阐述国家基本药物制度存在的问题,提出完善国家基本药物制度的对策。结果:我国虽制定了与《国家基本药物目录》相关的药物政策,但与世界卫生组织倡导的基本药物目标尚有较大差距,且存在法规体系不健全、政府宏观调控乏力、公众对基本药物认识不够、民众可获得基本药物不公平、基本药物制度建设滞后等问题。结论:我国基本药物法规体系亟待完善,民众对基本药物的认知和可获得性有待提高。应进一步提高基本药物的法律地位,强化《国家基本药物目录》的科学遴选、使用与监管,从而保障公众基本用药需求。

关 键 词:国家基本药物目录  制度  政策  对策
文章编号:1001-0408(2008)14-1041-04
修稿时间:2007年12月24

National Essential Drug Policy: Status Quo and Countermeasure
QIN Zheng-bi,WANG Zhi-hong,CHENG Gang,LI Yuan-qi,ZUO Xiao-ping,LU Zu-xun,XIANG Ji-zhou.National Essential Drug Policy: Status Quo and Countermeasure[J].China Pharmacy,2008,19(14):1041-1044.
Authors:QIN Zheng-bi  WANG Zhi-hong  CHENG Gang  LI Yuan-qi  ZUO Xiao-ping  LU Zu-xun  XIANG Ji-zhou
Institution:QIN Zheng-bi, WANG Zhi-hong,CHENG Gang,LI Yuan-qi,ZUO Xiao-ping ,LU Zu-xun, XIANG Ji-zhou,(1.School of Public Health, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430003, China;2.Liyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuchang 430071, China;3.Center for Drug Reevaluation, SFDA, Beijing 100045, China;4.Hubei Food and Drug Administration & ADR Monitoring Lenter, Wuhan 430071, China;5.Hubei Enshi State Food and Drug Administration, Enshi 445000, China)
Abstract:OBJECTIVE: To improve the national essential drug policy to meet the public demand on the public health care. METHODS: The problems existing in the national essential drug policy were analyzed by reviewing literature using comparative analysis. Some countermeasures were come up with for the system. RESULTS: The policy related to National Essential Drug List has been established in our country, but it still lags far behind the goal of essential drugs set by WTO. Some problems such as the imperfect laws and regulations, lack of the governmental macro-control, public' s lack of knowledge on the essential drugs, populace's unfair access to essential drugs, the backward construction of essential drug system etc can still be seen. CONCLUSION: The laws and regulations on national essential drugs should be evolved, people's recognition on and access to the essential drugs remain to be improved. The legal position of the essential drugs should be enhanced, and the selection, use and supervision of National Essential Drug List should be intensified to safeguard public's demand on medication.
Keywords:National essential drugs list  System  Policy  Countermeasure
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号